Handelsavisen
prelaunch
Companies Healthcare 388870.KQ
38
388870.KQ KOSDAQ Biotechnology & Medical Research

388870.Kq

$7 100,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
91,9B KRW
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
-77,2 %
Net margin
Debt / equity
0,57
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-77,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 388870.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 388870.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 25,511,878,170, significantly exceeding its total liabilities of KRW 15,942,556,870. The liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the current ratio of 18.96 indicates a robust ability to meet short-term obligations. The price-to-book ratio of 6.4 and price-to-tangible-book ratio of 6.4 suggest that the market is valuing the company's equity at a premium relative to its book value.

    Profitability metrics are negative, with a return on equity (ROE) of -0.7724 and a return on assets (ROA) of -0.3601, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at KRW -11,507,092,760, and the net income is also negative at KRW -10,756,653,750, reflecting ongoing losses. These figures are below the industry median for profitability metrics, suggesting underperformance relative to peers.

    The company's revenue is reported as zero, which may indicate a lack of disclosed revenue sources or a reporting anomaly. There is no information provided on segments or geographic exposure, making it difficult to assess revenue concentration or diversification. The absence of revenue data also complicates the evaluation of the company's growth trajectory and market position.

    The company's outlook for the current fiscal year is not explicitly provided, but the negative operating and net income figures suggest a challenging financial environment. The free cash flow is negative at KRW -9,961,893,890, and the operating cash flow is also negative at KRW -8,347,267,820, indicating that the company is not generating sufficient cash from operations to sustain its activities. The capital expenditure of KRW -42,724,140 suggests minimal investment in long-term assets, which may limit future growth potential.

    The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.57 suggests a moderate level of leverage, and the low dilution potential implies that the company is not likely to issue additional shares in the near term to raise capital. The absence of dilution flags and the low dilution potential are positive indicators for shareholders.

    Recent events, including filings and transcripts, do not show any significant developments that would impact the company's financial position or strategic direction. The company's financial statements do not indicate any major legal, regulatory, or operational issues that could affect its future performance.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 18.96, indicating a robust ability to meet short-term obligations.
    • Profitability metrics are negative, with a return on equity of -0.7724 and a return on assets of -0.3601, suggesting underperformance relative to industry standards.
    • The company's revenue is reported as zero, which may indicate a lack of disclosed revenue sources or a reporting anomaly.
    • The company is not generating sufficient cash from operations to sustain its activities, with a negative free cash flow of KRW -9,961,893,890.
    • The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
    • The company's capital expenditure is minimal, which may limit future growth potential.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $7 100,00
    Market cap
    $89.07B
    Enterprise value
    $71.50B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    6.4x
    P / Tangible book
    6.4x
    Tangible book
    $13.93B
    Net cash
    $17.57B
    Current ratio
    19.0
    Debt / equity
    0.6
    ROA
    -36.0%
    ROE
    -77.2%
    Cash conversion
    78.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-77,2 %Bottom quartile
    D/E0,57Bottom quartile
    Cash Conv0,78Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • 388870.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    388870.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage